Pediatric Infection and Vaccine

  • 제27권1호
  • /
  • Pages.45-52
  • /
  • 2020
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지
DOI QR코드

DOI QR Code

Carbapenem내성 Acinetobacter baumannii로 인한 인공호흡기연관 폐렴 환아에서 고용량 Ampicillin-Sulbactam 과 Colistin 항균제 병합요법의 치료적 예후: 예비 연구

Outcome of High Dose AmpicillinSulbactam and Colistin Combination Therapy for Treating VentilatorAssociated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: a Pilot Study

  • 정성희 (부산대학교 어린이병원 소아청소년과) ;
  • 김영아 (부산대학교 어린이병원 소아청소년과) ;
  • 최고은 (부산카톨릭대학교 진단검사의학과) ;
  • 박수은 (부산대학교 어린이병원 소아청소년과)
  • Jeong, Seong Hee (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Kim, Young A (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Choi, Go-eun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Park, Su Eun (Department of Pediatrics, Pusan National University Children's Hospital)
  • 투고 : 2019.08.14
  • 심사 : 2019.11.17
  • 발행 : 2020.04.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: Carbapenem-resistant Acinetobacter baumannii (CRAB)에 의한 인공호흡기연관 폐렴(ventilator-associated pneumonia, VAP)의 치료에 있어 고용량 ampicillin-sulbactam과 colistin의 병합요법 치료효과를 살펴보기 위한 예비 연구이다. 방법: 2017년도 6월부터 2018년도 8월까지 17명의 CRAB VAP 환자를 후향적으로 분석하였다. 10명(58.8%)의 환자는 고용량 ampicillin-sulbactam과 colistin 병합요법(병합치료군)으로 치료받았으며, 나머지 7명은 colistin 단독치료를 하였거나 colistin을 포함 또는 미포함하는 다양한 항균제의 병합치료(기타치료군)를 하였다. 본 연구는 두 그룹간의 임상 및 세균학적 결과를 비교하였다. 결과: 병합치료군에서 항균제 사용 후 발열기간은 1.30±1.70일이었고, 기타치료군에서는 1.71±1.49일이었다. 기관내관 흡인물 검체에서 균이 음전 될 때까지의 평균 기간은 병합치료군에서 3.40±1.71일 기타치료군에서 11.80±8.86일이었다(P=0.030). 항균제 치료 30일 이내 사망률은 병합치료균에서 1/10 (10%)이고 기타치료군에서 3/7 (42.9%)이었다. 결론: 소아의 CRAB에 의한 인공호흡기연관 폐렴 환자에서 고용량 ampicillin-sulbactam과 colistin의 병합요법이 임상적 예후를 개선시킬 수 있을 것으로 기대된다.

Purpose: This pilot study aimed to evaluate the efficacy of high dose ampicillin-sulbactam and colistin combination therapy for ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in the pediatric intensive care unit of Pusan National University Children's Hospital. Methods: We retrospectively reviewed 17 pediatric patients with VAP caused by CRAB from June 2017 to August 2018. Ten (58.8%) patients were treated with high dose ampicillin-sulbactam and colistin combination therapy (combination therapy group), whereas 7 were treated with colistin only or with various combinations with or without colistin (other antibiotics group). Clinical and bacteriological outcomes were compared between the groups. Results: The mean duration of fever after antibiotic use was 1.30±1.70 days in the combination therapy group and 1.71±1.49 days in the other antibiotics group. The mean duration of days for negative conversion of endotracheal aspirate bacterial culture after antibiotic therapy was 3.40±1.71 days in the combination therapy group and 11.80±8.86 days in the other antibiotics group. The mortality rate within 30 days of antibiotic therapy was 1/10 (10%) in the combination therapy group and 3/7 (42.9%) in the other antibiotics group. Conclusions: High dose ampicillin-sulbactam and colistin combination therapy as early antibiotic treatment in VAP caused by CRAB in children could improve clinical outcomes.

키워드

참고문헌

  1. Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 2014;59 Suppl 6:S388-93. https://doi.org/10.1093/cid/ciu594
  2. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014;33:1311-22. https://doi.org/10.1007/s10096-014-2070-6
  3. Kim YA, Park YS. Epidemiology and treatment of antimicrobial-resistant gram-negative bacteria in Korea. Korean J Intern Med 2018;33:247-55. https://doi.org/10.3904/kjim.2018.028
  4. Bae IK, Jeong SH, Lee K. Carbapenem-resistant Acinetobacter baumannii. Korean J Clin Microbiol 2012;15:1-8. https://doi.org/10.5145/KJCM.2012.15.1.1
  5. Park SY, Lee EJ, Kim T, Yu SN, Park KH, Lee MS, et al. Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia. Int J Antimicrob Agents 2018;51:407-12. https://doi.org/10.1016/j.ijantimicag.2017.10.018
  6. Lee HJ, Lee DG. Carbapenem-resistant Enterobacteriaceae: recent updates and treatment strategies. J Korean Med Assoc 2018;61:281-9. https://doi.org/10.5124/jkma.2018.61.4.281
  7. Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis 2012;55:852-9. https://doi.org/10.1093/cid/cis543
  8. Makris D, Petinaki E, Tsolaki V, Manoulakas E, Mantzarlis K, Apostolopoulou O, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med 2018;22:67-77. https://doi.org/10.4103/ijccm.IJCCM_302_17
  9. Hsu AJ, Tamma PD. Treatment of multidrug-resistant gram-negative infections in children. Clin Infect Dis 2014;58:1439-48. https://doi.org/10.1093/cid/ciu069
  10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25. Wayne: Clinical and Laboratory Standards Institute, 2015.
  11. Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria. Crit Care Med 2012;40:281-4. https://doi.org/10.1097/CCM.0b013e31822d7913
  12. Mularoni A, Bertani A, Vizzini G, Gona F, Campanella M, Spada M, et al. Outcome of transplantation using organs from donors infected or colonized with carbapenem-resistant gram-negative bacteria. Am J Transplant 2015;15:2674-82. https://doi.org/10.1111/ajt.13317
  13. Choi SJ, Moon CJ, Chun YH, Yoon JS, Kim HH, Kim JT, et al. PRISM III in a pediatric intensive care unit with multiple disease entities. Korean J Crit Care Med 2011;26:123-7. https://doi.org/10.4266/kjccm.2011.26.3.123
  14. Ko KS, Choi Y, Lee JY. Old drug, new findings: colistin resistance and dependence of Acinetobacter baumannii. Precis Future Med 2017;1:159-67. https://doi.org/10.23838/pfm.2017.00184
  15. Lee K, Yong D, Jeong SH, Chong Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 2011;52:879-91. https://doi.org/10.3349/ymj.2011.52.6.879
  16. Kim MJ, Lee HJ, Son SH, Huh JW. Outbreak of Acinetobacter septicemia in a neonatal intensive care unit. Korean J Pediatr 2006;49:494-9. https://doi.org/10.3345/kjp.2006.49.5.494

피인용 문헌

  1. Colistin/vancomycin : Acute kidney injury: case report vol.1762, pp.1, 2020, https://doi.org/10.1007/s40278-019-64858-9